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The photons of sunlight begin a series of genetic events
in skin leading to cancer. UV signature mutations
provide an alternative to inherited mutations as a way
of identifying genes that are involved in cancer
development. They augment epidemiologic and clinical
data by serving as molecular evidence for the role of
UV radiation in skin carcinogenesis. Signature mutations
are present in TP53 and PTCH, two tumor suppressor
genes responsible for non-melanoma skin cancer. We
review evidence that clones of TP53-mutated cells are
present in normal human and murine epidermis exposed
Mutations are pivotal in cancer development. Inaddition to their causal role, they constitute apermanent record of the events that created thecancer. In familial cancers, mutations are inherited.A genetic analysis of the patient and family members
may reveal direct links between genes and tumors. Inactivated genes
such as Rb in retinoblastoma (reviewed in Hooper, 1998; Gallie et al,
1999), APC in inherited familial adenomatous polyposis syndrome
(reviewed in de la Chapelle and Peltomaki, 1998; Fearon and Dang,
1999), or BRCA1 and BRCA2 in hereditary breast cancer (reviewed
in Blackwood and Weber, 1998; Duncan et al, 1998) have been shown
to contribute to tumors. Most tumors, however, are sporadic; the
mutations underlying behind these tumors occurred anew during DNA
replication in each somatic progenitor cell. Yet, in order to understand
sporadic cancers, the genes responsible for these tumors must be
identified. This can be best achieved by using a retrospective approach
in which DNA from tumors is analyzed in search of mutations. Several
genes have been identified using this approach, both oncogenes and
tumor suppressor genes. The role of mutations in cancer is currently
unquestioned, yet important steps of the process of cancer development
fall short of being explained. For example, the cause of these mutations
is largely unknown. This is primarily because mutagenic agents are
nearly countless whilst mutation types are limited to a few. Also,
important links are yet to be discovered concerning how a single
mutant cell slips past the body’s surveillance system to start becoming
a tumor. Steps that we find most intriguing are the earliest ones: the
acquisition of the first mutation and the rise of a clone from a single
mutated cell.
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to UVB and conclude that, in addition to being a
tumorigenic mutagen, sunlight acts as a tumor promoter
by favoring the clonal expansion of TP53 mutated cells.
These combined actions of sunlight result in normal
individuals’ carrying a substantial burden of ker-
atinocytes predisposed to cancer. Thus cancer involves
both a single-cell problem and a multi-cell problem;
in skin cancer, sunlight appears to drive both. Key
words: basal cell cancer/p53/PTCH/squamous cell cancer.
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UV SIGNATURE MUTATIONS
By definition, a mutation is a change in the sequence of the DNA.
This change is introduced upon incorporating a non-complementary
base into the strand being synthesized by DNA polymerase during
replication. Because mammalian polymerases have high fidelity, mistakes
most often occur when the template is altered and the enzyme
misinterprets it. Numerous factors cause base alterations (Table I), but
the resulting variety of mutations is much smaller. Mutations, therefore,
do not reflect a unique base alteration and in most cases the mutagen
remains untraceable. UV-induced mutations are exceptions. Certain
sequence patterns, such as two pyrimidine bases (cytosine or thymine)
adjacent to one another, are more susceptible to being damaged by
UV than other base combinations (Fig 1). Thus, UV generates a rather
distinct and homogeneous mutation pattern. It is also the pattern found
in skin tumors most frequently. In skin tumors cytosine (C) is commonly
replaced by thymine (T), but – because the photoproducts occur only
where two pyrimidines are adjacent – this mutation occurs only where
the C was next to a T or another C. Sometimes, two adjacent cytosines
(CC) are changed to TT. Such changes occur almost exclusively as a
result of UV. The C→T substitution may be instructed by the DNA
photoproduct (Lawrence, 1981; Miller, 1985; Drobetsky et al, 1987).
The ‘‘A rule’’ (Schaaper et al, 1983; Strauss, 1991) might also play a
role in the formation of UV signature mutations: DNA polymerases
treat some altered bases as if they were an adenine and incorporate a
thymine into the daughter strand.
Coexistence of two features thus makes skin cancer an ideal candidate
to study: they develop right in front of our eyes and they bear a
traceable mutation. The presence of UV signature mutations helps
identify the perpetrator. These signatures augment epidemiologic and
clinical data by serving as molecular evidence for the role of UV
radiation in skin carcinogenesis. Detecting these signatures from early
clinical lesions helps identify steps of skin carcinogenesis and genes of
the greatest importance.
TP53 is such a gene. Our knowledge regarding TP53 makes it one
of the best-understood pathways for revealing how a cell acquires a
mutation and how that mutation leads to cancer.
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Table I. The most common factors that cause alterations in
the chemical structure of the DNA, thus leading to mutations
Internal events External damage to DNA
1. Spontaneous base alterations 1. UV radiation
2. Tautomeric shifts 2. Chemical agents
3. Deamination of bases Alkylating agents
4. Depurination and Cross-linking agents
depyrimidination Psoralens




TP53 IN SQUAMOUS CELL CANCER
The TP53 tumor suppressor gene encodes a 53 kDa molecular weight
protein that functions as a transcription factor. That protein regulates
a number of genes that eventually lead to two major end-points: cell
cycle regulation and apoptosis (Lane, 1992). Induction of TP53 protein
can be seen as early as 30 min after exposure to UV (Maltzman and
Czyzyk, 1984). TP53 protein induction happens at the level of reduced
degradation, not transcription, because an increase in mRNA is not
detected. The half-life of the wild-type TP53 protein is short and the
signal usually disappears a few hours after induction (Ljungman and
Zhang, 1996). Mutated TP53, on the other hand, is relatively resistant
to degradation; this phenomenon can be used in immunohistochemical
staining to detect cells with potentially mutated TP53 (Hall and Lane,
1994). In the immunohistochemical reaction, a mono- or polyclonal
antibody is directed toward certain epitopes of the TP53 protein and
the antigen-antibody binding is visualized as a nuclear staining. Because
the basal level of TP53 protein expression is low in skin, a positive
immunohistochemistry signal can be seen if (i) TP53 is being expressed
in response to a recent physiologic stimulus such as UV (TP53 is wild-
type), or (ii) the protein has failed to undergo degradation (TP53 is
mutant). Some antibodies target mutated forms of TP53 by recognizing
epitopes that are accessible only when an amino acid change occurs in
the protein, thus allowing selective detection of mutated TP53. Yet,
the definitive determination requires DNA sequencing.
Sections from squamous cell cancer (SCC) contain a large number
of cells that are positive upon staining with an antibody against TP53
(Brash et al, 1991; Ziegler et al, 1993; Wikonkal et al, 1997). Sequencing
data from a large number of skin tumors showed that TP53 is mutated
in over 90% of SCC (Brash et al, 1991; Campbell et al, 1993; Ziegler
et al, 1993; Jonason et al, 1996; Ren et al, 1996). The most common
mutation was C→T at dipyrimidine sites, in about 70% of the cases.
Tandem CC→TT mutations were also found at a frequency of 10%;
these mutations have been shown to be exclusive to UV in different
systems. The remaining 20% of mutations in SCC have also been seen
in UV irradiated cells in culture but are not UV signature mutations
because they can be caused by other agents. Hence, two important
pieces of the cancer-formation puzzle become apparent: (i) UV is the
most prominent mutagenic agent in skin, and (ii) TP53 is one gene
that undergoes mutations. The high frequency of TP53 mutations, and
the fact that they all change an amino acid, indicates that a mutation
in this gene is a significant contributor to skin tumors. In internal
cancers, TP53 mutations are more diverse and virtually no mutations
resembling the characteristic UV signature were found (Greenblatt
et al, 1994).
Given that TP53 mutations caused by UV lead to SCC, one might
be able to use similar logic to find early forms of these tumors that
contain cells with UV signature mutations in the TP53 gene. A
condition related to sun exposure, actinic keratosis (AK), is considered
by dermatologists to be a forerunner to early SCC. The transitions
from severe sun damage to AK and from AK to in situ SCC have clear
histologic features: increasing number of mitoses, more evident cellular
atypia, and the appearance of the horn cysts characteristic to SCC.
These stages are clearly distinguishable in the histology and appear as
sequential steps (Lever, 1997). The similarity of AK to SCC is also
present at the molecular level. Work in our laboratory and by others
showed that AK, like SCC, contain cells that stain positively with
anti-TP53 antibodies. Moreover, these cells contain mutations and the
mutation pattern is similar to that of SCC (Ziegler et al, 1994). This
finding further supports the notion that TP53 mutations appear early
and play a critical role in the development of skin cancer.
To further address this question, we examined clinically normal skin.
Samples of skin from healthy individuals were collected from sun-
exposed and sun-protected areas. The epidermis was separated from
the dermis and the presence of TP53 was detected by immunohisto-
chemistry using anti-TP53 antibody. The epidermal sheets were then
analyzed for TP53 immunopositive nuclei under a light microscope.
We find clones of 60–1000 positive cells throughout sun-exposed
epidermis (Jonason et al, 1996). The anti-TP53 staining reveals two
distinct distributions of reactive keratinocytes. Sun-shielded skin harbors
only few TP53 positive cells and these cells appear either isolated or
in very small groups. Chronically sun-exposed skin, on the other hand,
contains more keratinocytes that stain positively with the anti-TP53
antibody than does sun-protected skin and the size of these ‘‘patches’’
is larger.
After microdissecting cells that stained positively with the antibody,
the DNA was isolated and exons of the TP53 gene were amplified by
polymerase chain reaction and sequenced. The sequencing reveals that
DNA of keratinocytes obtained from sun-exposed normal skin contains
mutations reminiscent of those seen in SCC and AK (Table II).
Normal skin from sun-protected skin areas does not contain mutations
(Ren et al, 1996). Two important features of the patches were also
analyzed: patch number and patch size. Patch frequency, expressed as
number of patches per cm2 skin area, shows a 10-fold difference
between sun-exposed and relatively sun-shielded skin such as abdomen
(Fig. 2). Patch size data are less straightforward to interpret because
of the large variation from patch to patch; however, a clear trend
toward larger patches in sun-exposed skin is apparent. Taken together,
these clones in skin chronically exposed to sunlight mean that chronic-
ally sun-exposed skin itself can be considered one of the earliest steps
in skin carcinogenesis.
In chronically sun-exposed skin, these clones are present at a
frequency of 35 clones per cm2 on average. The surprisingly high
number of TP53 immunoreactive patches directed our attention to
another fact. Comparing our numbers of TP53 patches to SCC
incidence, it is clear that only a small percentage of these TP53 positive
cells progress to tumors. Epidemiologic data show that less than 20%
of Caucasians develop SCC during their entire life. Therefore, most
of these clones either disappear or else remain but do not progress,
e.g., do not acquire additional mutations. Clones of mutated cells
disappear probably either by squaming off through regular keratinocyte
differentiation or by going through apoptosis. A clinical observation is
that human AK often regress if further sun-exposure is prevented
(Marks et al, 1986). In addition, apoptosis frequency in AK is higher
than in normal skin (Makino et al, 1998; Tsuji et al, 1998), which
speaks in favor of p53 independent apoptosis being the effector
mechanism.
Similar TP53 positive clones have been detected using CM-5 anti-
TP53 antibody in mouse skin after chronic UVB irradiation. This set
of experiments showed that TP53 positive clones arose in the skin of
hairless mice after 17 d of daily UVB exposures (Berg et al, 1996).
After 30 d of chronic UV exposure, the number of these positive cell
clusters increased. TP53 positive cells have also been observed in acute
experiments 12–24 h after a single UV exposure, largely because the
antibody recognizes both overexpressed wild-type and mutant p53.
The difference between the chronic irradiation staining and the acute
experiment is that p53 immunostaining observed after a single UV
exposure disappears 48–72 h after the UV treatment. Conversely, TP53
positive cells that were generated by repeated UV exposures remain
reactive with the antibody as long as 56 d after the irradiation ceased.
The length of time after which these cells still react with the
TP53 antibody suggests that keratinocytes in the chronic irradiation
experiment acquired a mutation in the p53 gene. To address this
question, PAb240, an antibody that recognizes only mutated forms of
p53, was used in an immunohistochemistry reaction. Epidermis from
a chronic experiment contained several patches stained positive with
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Table II. Patches of TP53 mutated keratinocytes in human epidermisa
Age Location Patch TP53 status
Sun shielded
YC19A 24 Inner arm 1 wt
YC17A 28 Abdomen 4 wt
YC7A 29 Breast 1 wt
YC8A 32 Breast 4 wt
YC4A 40 Lower abdomen 3 wt
YC13A 41 Breast 7 wt
YC18A 44 Inner arm 2 wt
YC14A 49 Lower abdomen 0 wt
YC6A 50 Breast 8 wt
Sun exposed
YC12A 9 Lip 46 wt
YC24A 43 Pre-auricular 23
YC5B.1 47 Pre-auricular (left) 29 T→Stop
YC5B.2 wt
YC5C 47 Pre-auricular (right) 45
YC2C.1 48 Lower eyelid 32 wt
YC2D.1 48 Pre-auricular 23 wt
YC2D.2 wt
YC2D.3 wt
YC2E 48 Pre-auricular 33
YC23A 51 Upper eyelid (right) 24
YC23B 51 Upper eyelid (left) 25
YC15A 53 Lower eyelid 44
YC15B.1 53 Lower eyelid 41 C→T
YC15B.2 C→T
YC1A 65 Upper eyelid (right) 36




YC22A 66 Upper eyelid (right) 33
YC22B 66 Upper eyelid (left) 25
YC11A 74 Pre-auricular 39
YC3A 79 Upper eyelid 27 wt
aYC numbers denote different individuals, letters denote different samples, and decimal numbers denote sequenced patches. Patch frequency is expressed as number of patches, regardless
of their pattern, per cm2. Base changes are indicated, otherwise wt stands for wild-type TP53. (from P.N.A.S. 24: 14025–14029, 1996)
the mutant specific antibody, whereas skin from mice after a single
UV exposure never did, suggesting that the p53 gene acquired
mutations after 17 d of irradiation (Berg et al, 1996). Given that chronic
UV irradiation results in a squamous cell cancer after 30–80 wk in
mice, the authors used sections of such UVB generated tumors as
positive controls. Twenty of 24 samples contain positive reacting cells
and nine of 10 PAb240 positive tumors contained mutations in the
p53; eight of them showed a C→T transition at dipyrimidine sites and
one had a CC→TT double transition. Immunoreactivity detected by
the PAb240 antibody shows excellent conformity with sequencing data.
These experiments revealed another aspect of chronic UVB exposure:
the TP53 positive clones gradually disappear after the UV irradiation
ceases. The longer the exposure persists, the slower the disappearance.
This result emphasizes the reversibility of these early precancerous
lesions. The flexibility of animal experiments, especially the ability to
control UV exposure, further supports the notion that TP53 clones
arise as daughter cells of a single TP53-mutated cell that acquired its
mutation by UV exposure.
TP53 IN BASAL CELL CANCER
Basal cell cancer (BCC) is quite different from SCC. For historic
reasons, textbooks still categorize BCC together with SCC under the
category ‘‘non-melanoma skin cancer’’. This distinction serves didactic
purposes, but has little relevance to the actual biology of these tumors.
The similarity between BCC and SCC is principally confined to
having the originating cell in common: the keratinocyte. The ker-
atinocyte origin explains why BCC and SCC lack pigmentation, as
opposed to the dark pigmentation seen in malignant melanoma. Among
other differences in the clinical picture, BCC have no clear precursor
lesions (Miller, 1991). The most important difference between BCC
and SCC is that BCC lack a key feature of cancers: metastasis. Some
even reason that BCC do not qualify as a ‘‘cancer’’ because they do
not metastasize. Differences between the clinical picture of BCC and
SCC do not appear to stem from differences at the TP53 level.
Mutation analysis of TP53 in BCC showed that 60%–100% of the
tumors contain mutations in the TP53 gene (Ziegler et al, 1993;
Ponte´n et al, 1997). Investigators needed alternative approaches to
BCC pathogenesis.
PTCH IN BCC
The possibility of other genes being involved in the pathogenesis of
BCC has been recently confirmed by identifying another gene that
plays a significant role in BCC formation: the human homolog of the
Drosophila ‘‘patched’’, PTCH (Hahn et al, 1996; Johnson et al, 1996;
Gailani and Bale, 1997). The gene was first cloned from Gorlin
syndrome patients. This autosomal dominant disorder, also called
‘‘nevoid basal cell carcinoma syndrome’’, is characterized by multiple
BCC. The syndrome includes striking congenital malformations such
as pits of the palms and soles, keratocysts of the jaw, midline brain
malformations, spine and rib abnormalities, ectopic calcification, macro-
cephaly with coarse facies, and generalized overgrowth (Springate,
1986; Gorlin, 1995).
Numerous PTCH mutations have been identified in unrelated
Gorlin patients, distributed across the gene (Chidambaram et al, 1996;
Hahn et al, 1996; Johnson et al, 1996; Unden et al, 1996; Wicking
et al, 1997). One-third of the mutations have been base substitutions,
nearly all leading to premature stop codons or splice-site mutations.
One-third were 1- or 2-bp deletions or insertions, resulting in
frameshifts, and another third were 4- to 76-base deletions or insertions.
Each kind of mutation would inactivate the protein, as expected for a
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tumor suppressor gene. The unusually high frequency of deletions and
insertions may be a feature of the PTCH gene or may simply reflect
the fact that mutations were obtained by first screening for single-
strand conformation polymorphisms. This assay misses many base
substitutions, but will be efficient at detecting larger mutations such as
deletions, insertions, or tandem substitutions. The larger mutations will
be effective anywhere in the gene, so they do not reveal whether the
gene has mutation hotspots or functionally important protein domains.
Figure 1. Two major photoproducts after UV absorption, the
cyclobutane pyrimidine dimer and the (6-4) photoproduct. The close
proximity of two pyrimidine rings is the foundation on which two major kinds
of chemical structure rearrangement can occur. The altered bases that are
formed after these rearrangements are referred to as photoproducts. The most
prevalent is the cyclobutane pyrimidine dimer (top right). It is generated when
the UV photon’s energy opens the double bonds between C atoms 5 and 6 of
two neighboring pyrimidine rings, whereupon two new bonds are established.
These covalent bonds are formed between the participating rings and link the
opposing C atoms of the two original rings. This structure is a four-member
ring itself, called the cyclobutyl ring. The second major photoproduct is the
pyrimidine-pyrimidone (6-4) photoproduct (bottom right). The foundation is
again two pyrimidine bases lying next to one another. If struck by UV, similarly
to the cyclobutane dimer formation, first the C-5 – C-6 double bond opens.
The subsequent events are, however, different. One of the pyrimidine rings
rotates and its C-4 atom forms a new bond with C-6 atom of the other ring.
In this case, only one new bond is formed: between atom C-6 in one of the
neighboring pyrimidone/pyrimidine rings and C-4 in the other.
Figure 2. Frequency and size of keratinocyte patches with positive immunohistochemical reaction against TP53. Samples of normal skin from healthy
individuals were collected from chronically sun-exposed, intermittently sun-exposed, and sun-shielded areas. After separating the epidermis, the presence of TP53
was studied by immunohistochemistry using anti-TP53 antibody. The epidermal sheets contained clones of cells with immunopositive nuclei at a frequency of 35
clones per cm2 (Jonason et al, 1996) in sun-exposed skin. On the other hand, in sun-shielded skin, only few TP53 positive cells were found and these cells appeared
in a scattered pattern (left panel). The size of the patches (right panel) showed a large variation from patch to patch; however, patches in sun-exposed skin were
larger than intermittently sun-exposed or sun-shielded skin.
Of 23 sporadic BCC, one-third had PTCH alterations detectable by
screening for single-strand conformation polymorphisms (Gailani et al,
1996; Hahn et al, 1996; Johnson et al, 1996; Unden et al, 1996).
Direct sequencing of two BCC without allelic loss or conformation
polymorphisms showed point mutations in both, suggesting that nearly
all BCC contain PTCH mutations (Gailani et al, 1996). The mutations
in sporadic BCC were somewhat different from those of Gorlin
syndrome patients. Over half were base substitutions and these often
led to amino acid changes. Only a third were small or large deletions
or insertions. One missense mutation near the 39 end of the coding
sequence was recently identified in a family with basal cell carcinomas
but no other stigmata of the Gorlin syndrome. Thus, it is possible that
some patients with multiple basal cell carcinomas, but no family history,
are actually new cases of a milder form of Gorlin syndrome.
The function of PTCH is still less clear than that of TP53. PTCH
belongs to the hedgehog signal transduction pathway that transmits
extracellular growth and differentiation signals to the nucleus. The
most common vertebrate homolog of hedgehog is sonic hedgehog
(SHH). The SHH gene is required for correct patterning of the neural
tube and somites and for anterior/posterior positioning of the limb
bud (Riddle et al, 1993; Roelink et al, 1995). This list of target tissues
corresponds well with the clinical features of Gorlin syndrome, which
include abnormalities of the brain, ribs, vertebrae and limbs. In addition,
PTCH is expressed in all the target tissues of sonic hedgehog. Transgenic
mice overexpressing the SHH gene develop many features of Gorlin
syndrome, and a SHH mutation has been identified in a BCC (Fan
et al, 1997; Oro et al, 1997).
A MODEL FOR CANCER DEVELOPMENT
The multiple steps that take TP53-mutated clones into a cancer appear
to have a genetic origin, with successive oncogenes or tumor suppressor
genes sustaining a mutation. These intervening steps – such as a
precancer – are unstable intermediates. Recent molecular and cellular
discoveries tell us what clinicians have long known – that cancer is
not an inevitable process. The early steps are each reversible. On a
sunny day at the beach, DNA repair enzymes remove and replace
most nucleotides struck and chemically rearranged by UV. Of the
molecular lesions overlooked, few cause mutations; most are correctly
bypassed during DNA replication and repaired later. Some cells with
unrepaired DNA damage vanish by TP53-directed apoptosis. Even
mutated cells do not progress inexorably. Work on DNA viruses has
revealed that cells with an aberrant cell cycle undergo apoptosis
(Morgenbesser et al, 1994; Symonds et al, 1994). Mutant cells thus are
in equilibrium between clonal expansion and regression. This balance
may explain the observation in the clinic that actinic keratoses regress
in the absence of sunlight exposure (Marks et al, 1986). Similarly, the
TP53-mutant clones seen in normal mouse skin begin to disappear
after UV irradiation ceases (Berg et al, 1996). Conversely, if another
genetic hit occurs before the previous DNA aberration, or aberrant
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Figure 3. Proposed model of SCC
formation. An unrepaired photoproduct
leads to a mutation in an epidermal cell. If
the mutation occurred in one allele of the
TP53 gene, the cell can fail to undergo
apoptosis and thereby gain a proliferative
advantage over normal cells, with AK
developing. Continued exposure to UV
might then inactivate the remaining functional
allele of TP53, which could accelerate the
formation of SCC by promoting genetic
instability.
cell, has been disposed of, the likelihood of tumor formation increases.
For example, cells with one allele of TP53 mutated are partially
deficient in apoptosis, but cells with two defective TP53 alleles begin
to amplify genes and become aneuploid (Yin et al, 1992). Our model
(Fig 3) begins with the observation that the UVB component of
sunlight creates cyclobutane dimers and (6-4) photoproducts in the
DNA molecule and some of these lesions slip past the repair system
to cause mutations. If a mutation occurs in the TP53 gene, the cell
involved shows one of the cellular phenotypes of TP53 mutations:
resistance to sunlight-induced apoptosis. Cells that fail to die may gain
a proliferative advantage over normal cells, with actinic keratosis
developing. Continued exposure to UV could then inactivate the
remaining functional allele of p53, further accelerating the formation
of squamous cell carcinoma by promoting genetic instability. This is
the point of no spontaneous return. A skin cancer appears and we
next see the patient in the physician’s office.
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